Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection
Background Experience from influenza pandemics suggested that convalescent plasma
treatment given within 4 to 5 days of symptom onset might be beneficial. However, robust
treatment data are lacking. Methods This is a multicenter, prospective, double-blind,
randomized controlled trial. Convalescent plasma from patients who recovered from the
2009 pandemic influenza A (H1N1)(A [H1N1]) infection was fractionated to hyperimmune IV
immunoglobulin (H-IVIG) by CSL Biotherapies (now BioCSL). Patients with severe A (H1N1) …
treatment given within 4 to 5 days of symptom onset might be beneficial. However, robust
treatment data are lacking. Methods This is a multicenter, prospective, double-blind,
randomized controlled trial. Convalescent plasma from patients who recovered from the
2009 pandemic influenza A (H1N1)(A [H1N1]) infection was fractionated to hyperimmune IV
immunoglobulin (H-IVIG) by CSL Biotherapies (now BioCSL). Patients with severe A (H1N1) …